



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Anti-EGFR [2F8 (Zalutumumab; HuMax-EGFR)] Standard Size Ab01677-10.0

**Isotype and Format:** Human IgG1, Kappa

**Clone Number:** 2F8 (Zalutumumab; HuMax-EGFR)

**Alternative Name(s) of Target:** ERBB1; ERBB; Erb-B2; HER1; Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1

**UniProt Accession Number of Target Protein:** P00533

**Published Application(s):** FC, ELISA, WB

**Published Species Reactivity:** Human

**Immunogen:** The original monoclonal antibody was generated by immunizing HuMAb mice with alternating A431 cells and purified EGFR administration.

**Specificity:** This antibody binds domain III of the human epidermal growth factor receptor (EGFR).

**Application Notes:** This antibody blocks the binding of EGF and TGF- $\alpha$  to the EGFR. At saturating concentrations, 2F8 completely blocked EGF-R signaling and inhibited the in vitro proliferation of EGF-R-overexpressing A431 cells. At much lower concentrations, associated with low receptor occupancy, 2F8 induced efficient Ab-dependent cell-mediated cytotoxicity (ADCC) in vitro. In vivo studies showed potent antitumor effects in models with A431 tumor xenografts in athymic mice. Flow cytometry was used to analyze the binding of mAb 2F8 to EGFR overexpressing A431 cells. mAb 2F8 was found to bind to membrane-associated EGF-R with an EC50 of approximately 1 µg/ml (7 nM). The ability of mAb 2F8 to block ligand-induced receptor phosphorylation was determined using immunoblotting. ELISA was used to determine whether mAb 2F8 had a functional C1q binding site (Bleeker et al., 2004). Phase I/II clinical trials and pharmacokinetic studies in patients with advanced squamous cell carcinoma of the head and neck revealed that 2F8/HuMax-EGFR can be safely administered in doses up to 8 mg/kg (Bastholt et al., 2007). Antibody 2F8 binds the domain III of the EGFR and locks it into a very compact and inactive conformation. Biochemical analyses showed bivalent binding of 2F8 to provide potent inhibition of EGFR signaling (Beuren et al., 2008). EGFRvIII-specific CDC was significantly enhanced when zalutumumab was combined with a Fc-engineered variant of antibody MR1-1 (Klausz et al., 2011).

**Antibody First Published in:** Bleeker et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. *J Immunol.* (2004); 173(7):4699-707. [PMID:15383606](#)

**Note on publication:** Describes the characterization of this antibody.

## Product Form

**Size:** 200 µg Purified antibody.

**Purification:** Protein A affinity purified

**Supplied In:** PBS with 0.02% Proclin 300.

**Storage Recommendation:** Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.